Group items tagged

Former Prime Minister Theresa May has formally opened new offices of LEO Pharma UK and Ireland during a launch event in Maidenhead, Berkshire. The company said on Friday (June 16) that the new building, based at Foundation Park, will function as its UK and Ireland operational headquarters. LEO Pharma has been manufacturing dermatology products in the UK and Ireland for over 60 years and continues its commitment to the Maidenhead area, where it been based for 10 years. The grounds offer state-of-the-art facilities and a greener and more sustainable workplace, the company said and hoped that that strong transport connections at Foundation Park will allow for seamless international collaboration, while a range of health and wellness initiatives will contribute to employee wellbeing. This new space will enable a collaborative and flexible work environment for LEO Pharma staff, ensuring they can continue to work to improve the lives of people living with skin conditions, their families and society.

Pharmaceutical recalls are complicated and expensive, just like in any other business. Pharmaceutical recalls, however, pose a further risk because they might change both short- and long-term health effects. To ensure smooth recalls with few negative effects on public health, it is crucial to understand the pharmaceutical product recall procedure and the roles of each key player. Throughout the recall procedure, patient safety is crucially ensured by the FDA, pharmaceutical companies, pharmacy technicians, and other healthcare professionals. Learning about pharma recalls, procedures, and responsibilities is essential for guaranteeing patient safety for key actors like the Food and Drug Administration (FDA), manufacturers, and other medical specialists. RECALL CLASSIFICATIONS Recalls can fall into one of three categories-class I, II, or III-with class I being the most serious and lethal. Products that have the potential to result in serious, permanent complications or death are subject to Class I recalls. Class II recalls are recommended for product flaws that have a low likelihood of harmful events or that can result in reversible side effects. Last but not least, class III recalls typically arise from problems with packaging that do not pose a risk. Since they are frequently issued out of an abundance of prudence rather than due to any negative impacts, many people may even describe this kind of recall as benign.

Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for selling adulterated or fake products, a government source said on Thursday. India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22. But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by India-based pharmaceutical companies. Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken. "There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event. Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had direct knowledge of the matter, told Reuters news agency.

Asian Media Group will hold the inaugural Pharmacy Business Diversity Conference on Thursday December 9 - a ground-breaking event exploring and showcasing diversity and inclusion in the pharmaceutical industry. The conference, themed 'Change the Ratio', will be be chaired by BBC presenter Clive Myrie and held virtually between 10am and 5pm. While both both RPS and ABPI are supporting the conference as associate sponsors, Well Pharmacy, the UK's largest independent pharmacy chain, is the headline sponsor of the event that will have some of Britain's most inspiring leaders and influential diversity and inclusion practitioners. These leaders will share their knowledge and experience whilst offering tangible steps to positively promote and implement diversity, inclusion and equality in workplace. Check pharmacy business website for more information.

A new residential building named after Dr Yusuf Hamied has opened at Christ's College, Cambridge, where the head of the Indian pharma giant, Cipla, was an undergraduate and then PhD chemistry student between 1954 and 1960. In more than 800 years that Cambridge University has been in existence, this is the first time an entire building has been named after an Indian. The "grand opening of Yusuf Hamied Court" at Christ's was presided over by Lord Simon McDonald, the Master of the College, and attracted about 25 leading scientists, mostly chemistry professors. Professor Sir Venkatraman Ramakrishnan, a chemistry Nobel Prize winner and a former president of the Royal Society, was also present at the event earlier this month, as well as Dr Anthony Freeling, the acting vice-chancellor of Cambridge University, and the chemist Dame Mary Archer, wife of the best-selling novelist Jeffrey Archer. Hamied and McDonald posed for photographs in front of the "entirely green" four-storey building, where the 64 rooms for postgraduates and fellows from around the world will rely on heat exchangers, instead of gas.

The Royal Pharmaceutical Society (RPS) is seeking views of pharmacists to help shape the future of pharmacy practice in England over the next decade. The RPS's project with The King's Fund, transforming pharmacy practice, aims to develop a vision for the role of pharmacists and pharmacy teams working across systems, providing patient care and NHS services. It's due to be published at the end of the year. "From 15 August to 30 September we are asking people to respond to our consultation on six key themes," the RPS said. "We'll also be holding face-to-face and virtual events in September to hear your views." The King's Fund has completed a literature review which has helped inform the initial six themes which will be the focus of the consultation, all of which can be downloaded and read before responding.